Melola Discovery

← Melola Discovery

Jurnal SINTA 1

A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients

ACTA MEDICA INDONESIANA · Vol. 51 No. 4 (2020)

ISSN
2338-2732, 0125-9326
Terbit
2020-02-10
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9: 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p <0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 275 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Institut Agama Islam Negeri Bone
  • Hasanuddin University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kuntjoro HarimurtiAfiliasi tidak diketahui11
Muhammad Khifzhon AzwarAfiliasi tidak diketahui7
Noto DwimartutieAfiliasi tidak diketahui6
Hamzah ShatriAfiliasi tidak diketahui6
Rahmi IstantiAfiliasi tidak diketahui6
Roza MulyanaAfiliasi tidak diketahui5
Rensa RensaAfiliasi tidak diketahui5
Jessica MarsigitAfiliasi tidak diketahui5
Nur RiviatiAfiliasi tidak diketahui4
Aulia RizkaAfiliasi tidak diketahui4
Ikhwan RinaldiAfiliasi tidak diketahui4
Cleopas Martin RumendeAfiliasi tidak diketahui4
Eka Dian SafitriAfiliasi tidak diketahui4
Siti Rizny F SaldiAfiliasi tidak diketahui4
Rudi PutrantoAfiliasi tidak diketahui4
Rudy HidayatAfiliasi tidak diketahui4
Purwita W LaksmiAfiliasi tidak diketahui3
Tirza Z TaminAfiliasi tidak diketahui3
Dyah PurnamasariAfiliasi tidak diketahui3
Esthika DewiastyAfiliasi tidak diketahui3
Ari Fahrial SyamAfiliasi tidak diketahui3
Muhammad YaminInstitut Agama Islam Negeri Bone3
Simon SalimAfiliasi tidak diketahui3
Eric Daniel TendaAfiliasi tidak diketahui3
Muhammad K AzwarAfiliasi tidak diketahui3
Ika FitrianaHasanuddin University3
Imam SubektiAfiliasi tidak diketahui3
I Gusti Putu Suka AryanaAfiliasi tidak diketahui3
Yudo Murti MupangatiAfiliasi tidak diketahui3
Sri SunartiAfiliasi tidak diketahui3
Fatichati BudiningsihAfiliasi tidak diketahui3
Lazuardhi DwipaAfiliasi tidak diketahui3
Agus SudarsoAfiliasi tidak diketahui3
Pradana SoewondoAfiliasi tidak diketahui3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients</dc:title>
	<dc:creator>Dewi, Sumartini</dc:creator>
	<dc:creator>Isbagio, Harry</dc:creator>
	<dc:creator>Purwaningsih, Erni Hernawati</dc:creator>
	<dc:creator>Kertia, Nyoman</dc:creator>
	<dc:creator>Setiabudy, Rianto</dc:creator>
	<dc:creator>Setiati, Siti</dc:creator>
	<dc:subject xml:lang="en-US">Physalis angulata Linn</dc:subject>
	<dc:subject xml:lang="en-US">modified Rodnan’s skin score (MRSS)</dc:subject>
	<dc:subject xml:lang="en-US">erythrocyte sedimentation rate (ESR)</dc:subject>
	<dc:subject xml:lang="en-US">procollagen type-1 N terminal proteinase (P1NP)</dc:subject>
	<dc:subject xml:lang="en-US">scleroderma</dc:subject>
	<dc:subject xml:lang="en-US">Scleroderma</dc:subject>
	<dc:description xml:lang="en-US">Background: scleroderma is an autoimmune disease characterized by organ fibrosis, resistant to standard treatment. It is suspected the addition of Physalis angulata Linn. (Ciplukan) extract as adjuvant therapy can improve the scleroderma skin fibrosis. The aim at this study is to evaluate the effect of ciplukan extract as adjuvant on scleroderma skin fibrosis in standard therapy, based on modified Rodnan skin scale (MRSS), inflammatory biomarkers, immunology and serum fibrosis. Methods: double-blind, randomized clinical trial was performed in scleroderma patients with stable disease at Cipto Mangunkusumo hospital and Hasan Sadikin hospital during November 2015−March 2017 who met the selection criteria and continued to receive standard therapy. The subjects were randomly allocated into two groups: the study group received the ciplukan  extract 3 x 250 mg / day for 12 weeks and the placebo group. Examination of MRSS, ESR, P1NP, BAFF and sCD40L was performed every 4 weeks until the end of the study. Results: fifty-nine subjects completed the study. They consisted of 29 subjects of the treatment group and 30 of the placebo group, with an average age of 41 (SD 9) years, the proportion of women: male = 9 : 1. There was a significant improvement of skin fibrosis in the study group with a highly significant decrease in MRSS (35.9% VS 6.3%, p &amp;lt;0.001) and a relative decrease in P1NP levels (17.8% VS 0.7%, p = 0.002). No decrease in ESR, BAFF and sCD40L levels in both groups. There was a weak but significant positive correlation between MRSS with P1NP levels (r = 0.236, p = 0.036). Conclusion: Ciplukan extract with dose 3 x 250 mg for 12 weeks as adjuvant on scleroderma standard therapy alleviates skin fibrosis significantly based on MRSS and P1NP levels.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2020-02-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">clinical trial</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1387</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 51 No. 4 (2019): Acta Medica Indonesiana; 303</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1387/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2020 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>